<DOC>
	<DOCNO>NCT02478242</DOCNO>
	<brief_summary>Randomized study evaluate efficacy safety nafamostat mesilate use continuous renal replacement therapy acute kidney injury patient high risk bleeding .</brief_summary>
	<brief_title>Trial Assess Efficacy Safety Nafamostat Mesilate During Continuous Renal Replacement Therapy</brief_title>
	<detailed_description>Patients randomly assign nafamostat mesilate ( NM ) group anticoagulant ( NA ) group . In patient assigned NM group , NM ( 20mg/h ) use maintenance anticoagulation . Whereas , patient assign NA group , normal saline ( 2mL/h ) infuse continuous renal replacement therapy .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Nafamostat</mesh_term>
	<criteria>Patients admit intensive care unit require CRRT 1. active bleed gastrointestinal bleeding intracranial hemorrhage , 2. activate partial thromboplastin time &gt; 60 , 3. prothrombin timeinternational normalize ratio &gt; 2.0 , 4. thrombocytopenia ( &lt; 100,000/ÂµL ) , 5. surgery within 48 h CRRT . Pregnant possibly pregnant woman Patients allergic nafamostat mesilate Patients hypercoagulable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>